Physicians' Acceptance of Pharmacists' Intervention involving prescription review and risk assessment in Type 2 Diabetes Mellitus Patients Attending three Healthcare Facilities, Ilorin
DOI:
https://doi.org/10.51412/psnnjp.2025.36Keywords:
pharmacist-physician, collaboration, physician acceptance, pharmacist's intervention, T2DM, NigeriaAbstract
Introduction: Clinical pharmacists review medication orders from prescribers to avert drugrelated problems (DRPs). The aim of the study was to assess physician acceptance rate of pharmacist's intervention in out-patients with type 2 diabetes mellitus attending three healthcare facilities.
Method: This study was a prospective study (N=138) among out-patients with Type 2 Diabetes mellitus attending three health facilities. Interventions involved DTP checks, dyslipidemia/CKD risk blood tests, Framingham risk, and physician notification. Study was carried out between the months of September 2023 to October 2023. For categorical parameters, the frequencies were calculated, and the results were expressed in descriptive statistics using chi-square, p-value < 0.05 was considered as statistically significant.
Results: Of the respondents 61.6% (85) were females while 38.4% (53) were males. Age range of 60-69 had the highest response (41, 29.7%). Overall physician acceptance rate of pharmacist's interventions was 100.0%. The most common interventions accepted by physicians include addition of statins to respondent's medications due to moderate to high cardiovascular disease risk score, need to monitor lipid profile, and institution of adherence program.
Conclusion: Overall physician acceptance rate of pharmacist's interventions was 100.0%. The most commonly accepted were adding statins for patients with moderate to high cardiovascular risk, monitoring lipid profiles, and initiating adherence programs for non-adherent patients.
References
1. Zaal RJ, den Haak EW, Andrinopoulou ER, van Gelder T, Vulto AG, van den Bemt PMLA. Physicians' acceptance of pharmacists'
interventions in daily hospital practice. Int J Clin Pha rm. 2020 Feb;42(1):141-149. doi: 10.1007/s11096-020-00970-0.
2. Zaman Huri H, Chai Ling L. Drug-related problems in type 2 diabetes mellitus patients with dyslipidemia. BMC Public Health. 2013 Dec 17;13:1192. doi: 10.1186/1471-2458-13-1192.
3. Bedouch P, Allenet B, Grass A, Labarère J, Brudieu E, Bosson JL, Calop J. Drug-related problems in medical wards with a computerized physician order entry system. J Clin Pharm Ther. 2009 Apr;34(2):187-95. doi: 10.1111/j.1365-2710.2008.00990.x.
4. Auta A, Strickland-Hodge B, Maz J. Challenges to clinical pharmacy practice in Nigerian hospitals: a qualitative exploration of stakeholders' views. J Eval Clin Pract. 2016 Oct;22(5):699-706. doi: 10.1111/JEP.12520.
5. David EA, Soremekun RO, Abah IO, AderemiWilliams RI. Impact of pharmacist-led care on glycaemic control of patients with uncontrolled type 2 diabetes: a randomised controlled trial in Nigeria. Pharm Pract (Granada). 2021 JulS e p ; 1 9 ( 3 ) : 2 4 0 2 . d o i: 10.18549/PHARMPRACT.2021.3.2402.
6. Bedouch P, Charpiat B, Conort O, Rose FX, Escofier L, Juste M, Roubille R, Allenet B. Assessment of clinical pharmacists' interventions in French hospitals: results of a multicenter study. Ann Pharmacother. 2008 Jul;42(7):1095-103. doi: 10.1345/APH.1L045.
7. Le e J, McPh e rs o n ML. Ou t c ome s o f recommendations by hospice pharmacists. Am J Health Syst Pharm. 2006 Nov 15;63(22):2235-9. doi: 10.2146/AJHP060143.
8. Okonta JM, Okonta EO, Ofoegbu TC. Barriers to Implementation of Pharmaceutical Care by Pharmacists in Nsukka and Enugu metropolis of Enugu State. J Basic Clin Pharm. 2012 Mar; 3(2): 295 - 8. doi: 10.4103/0976 -0105.103823.
9. Oladipo H, Muili A, Rashidat Y, Rokibat A. The Role of Pharmacists in Strengthening the Health System in Nigeria. Innov Pharm. 2022 Dec 12;13(2):10.24926/iip.v13i2.4673. doi: 10.24926/IIP.v13i2.4673.
10. Auta A, Strickland-Hodge B, Maz J. Challenges to clinical pharmacy practice in Nigerian hospitals: a qualitative exploration of stakeholders' views. J Eval Clin Pract. 2016 Oct;22(5):699-706. doi: 10.1111/JEP.12520.
11. Achi C. Physician–Pharmacist collaboration in healthcare services in Nigeria from 1980-2020: a narrative review. Journal of Current Biomedical Research. 2021 Dec 22;1(3):80-92.
12. Bondesson A, Holmdahl L, Midlöv P, Höglund P, Andersson E, Eriksson T. Acceptance and importance of clinical pharmacists' LIMM-based recommendations. Int J Clin Pharm. 2012 Apr;34(2):272-6. doi: 10.1007/s11096-012-9609-3.
13. Zweben A, Piepmeier ME, Fucito L, O'Malley SS. The clinical utility of the Medication Adherence Questionnaire (MAQ) in an alcohol pharmacotherapy trial. J Subst Abuse Treat. 2017 Jun;77:72-78. doi: 10.1016/J.JSAT.2017.04.001.
14. WebMD. Drug Interaction Checker [Internet]. New York: WebMD, LLC; [cited 2025 Apr18]. Available from:
https://www.webmd.com/interaction-checker/default.htm
15. Pharmaceutical Care Network Europe Foundation: 2006, PCNE classification for drugrelated problems version 5.01. 2006, Retrieved October 22, 2011, from http://www.pcne.org/sig/drp/documents/PCNE%20classification%20V5.01.pdf
16. Kaze AD, Santhanam P, Musani SK, Ahima R, Echouffo-Tcheugui JB. Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study. J Am Heart Assoc. 2021 Apr 6;10(7):e016947. doi: 10.1161/JAHA.120.016947.
17. Wu B, Bell K, Stanford A, Kern DM, Tunceli O, Vupputuri S, Kalsekar I, Willey V. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Res Care. 2016 Apr 11;4(1):e000154. doi: 10.1136/BMJDRC2015-000154
18. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018 Jun 8;17(1):83. doi: 10.1186/s12933-018-0728-6.
19. Wu B, Bell K, Stanford A, Kern DM, Tunceli O, Vupputuri S, Kalsekar I, Willey V. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Res Care. 2016 Apr 11;4(1):e000154. doi: 10.1136/BMJDRC2015-000154
20. Aliyu FO. Prevalence of chronic kidney disease in patients with type 2 diabetes mellitus attending a secondary care hospital in north central Nigeria. J. Pharm. Res. Dev. & Pract. 2021 Apr; 5(1):036-42
21. Ioannidis I. Diabetes treatment in patients with renal disease: Is the landscape clear enough? World J Diabetes. 2014 Oct 15;5(5):651-8. doi: 10.4239/WJD.v5.i5.651.
22. Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. Am J Kidney Dis. 2018 Mar;71(3):362-370. doi: 10.1053/J.AJKD.2017.08.017.
23. Aliyu FO, Orimogunje T, Bello SI, Abdulbaki M, Jamiu MO, Ogaji IJ. Prevalence of Dyslipidemia, Drug Therapy Problems, and Medication Adherence in Type 2 Diabetes Mellitus Patients in North Central Nigeria. Libyan International Medical University Journal. 2024 Feb 16. doi.org/10.1055/s-0044-1779340 .
24. Artime E, Romera I, Díaz-Cerezo S, Delgado E. Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review. Diabetes Ther. 2021 Jun;12(6):1631-1659. doi: 10.1007/s13300-021-01060-8.
25. Regassa LD, Tola A, Ayele Y. Prevalence of Cardiovascular Disease and Associated Factors Among Type 2 Diabetes Patients in Selected Hospitals of Harari Region, Eastern Ethiopia. Front Public Health. 2021 Feb 5;8:532719. doi: 10.3389/FPUBH.2020.532719.
26. Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D'Agostino RB Sr. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care. 2008 Aug;31(8):1582-4. doi: 10.2337/DC08-0025.
27. Wabe NT, Angamo MT, Hussein S. Medication adherence in diabetes mellitus and self management practices among type-2 diabetics in Ethiopia. N Am J Med Sci. 2011 Sep;3(9):418-23. doi: 10.4297/NAJMS.2011.3418.
28. Jahangiry L, Farhangi MA, Rezaei F. Framingham risk score for estimation of 10-years of cardiovascular diseases risk in patients with metabolic syndrome. J Health Popul Nutr. 2017 Nov 13;36(1):36. doi.org/10.1136/EJHPHARM2014-000491
29. Durand A, Gillibert A, Membre S, Mondet L, Lenglet A, Mary A. Acceptance Factors for InHospital Pharmacist Interventions in Daily Practice: ARetrospective Study. Front Pharmacol. 2022 Mar 23; 13: 811289. doi: 10.3389/FPHAR.2022.811289.
30. Bouzeid M, Clarenne J, Mongaret C, Pluchart H, Chanoine S, Vermorel C, SFPC VIP–Act-IP© group Bedouch Pierrick Bourdelin Magalie Charpiat Bruno Conort Ornella Gravoulet Julien Janoly-Dumenil Audrey Juste Michel Mongaret Céline, Bosson JL, Bedouch P. Using national data to describe characteristics and determine acceptance factors of pharmacists' interventions: a six-year longitudinal study. International Journal of Clinical Pharmacy. 2023 Apr;45(2):430-41. doi.org/10.1007/IJCP.S11096-022-01526-0
31. Zillich AJ, McDonough RP, Carter BL, Doucette W R . Influential characteristics of physician/pharmacist collaborative relationships. Ann Pharmacother. 2004 May;38(5):764-70. doi: 10.1345/APH.1D419.
32. Usifoh SF, Soni JS and Asemah MR. Pharmacists -Medical Doctors Work Relationship and Its Effect on Patient Care in Benin-City, Edo State. Journal of Science and Practice of Pharmacy; (2019). 6 (1): 309-315. doi.org/10.47227/JSPPHARM/v6i1.5
33. Lindenmeyer A, Hearnshaw H, Vermeire E, Van Royen P, Wens J, Biot Y. Interventions to improve adherence to medication in people with type 2 diabetes mellitus: a review of the literature on the role of pharmacists. J Clin Pharm Ther. 2006 Oct;31(5):409-19. doi: 10.1111/j.1365-2710.2006.00759.x.
34. Williams JL, Walker RJ, Smalls BL, Campbell JA, Egede LE. Effective interventions to improve medication adherence in Type 2 diabetes: a systematic review. Diabetes Manag (Lond). 2014 Jan 1;4(1):29-48. doi: 10.2217/DMT.13.62
Downloads
Views | PDF Downloads:
0
/ 0
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
